28.01.2023 Views

CENSIS white paper: Intellectual Property in Business

2023: This CENSIS white paper sets out to make the topic of IP more approachable, less intimidating and more manageable, offering experience-based advice and methods are are designed to help businesses structure their IP- related issues and makes the best of their IP. Covering: The role of IP, IP management during growth, IP strategy for expanding companies and corporates, Business IP Canvas - merging IP with your business model.

2023: This CENSIS white paper sets out to make the topic of IP more approachable, less intimidating and more manageable, offering experience-based advice and methods are are designed to help businesses structure their IP- related issues and makes the best of their IP.
Covering:
The role of IP, IP management during growth, IP strategy for expanding companies and corporates, Business IP Canvas - merging IP with your business model.

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Intellectual</strong> <strong>Property</strong> <strong>in</strong> Bus<strong>in</strong>ess: IP basics, IP management, IP strategy<br />

IP Management dur<strong>in</strong>g Growth (cont<strong>in</strong>ued)<br />

13 What to do with your IP<br />

When it comes to decisions relat<strong>in</strong>g to IP strategy,<br />

companies must answer one key question: whether to<br />

pursue a closed, open or semi-open strategy.<br />

John Palfrey gives an <strong>in</strong>terest<strong>in</strong>g perspective on the<br />

use of IP and divides the spectrum of uses <strong>in</strong>to three<br />

categories: full exclusion (closed), limited exclusion<br />

(semi-open) and unlimited exclusion (open).<br />

Full exclusion<br />

You decide to exclude everyone else from us<strong>in</strong>g<br />

some or all of your <strong>in</strong>tellectual property and exploit it<br />

yourself to the greatest extent allowable under law. This<br />

approach corresponds with a common understand<strong>in</strong>g<br />

of <strong>in</strong>tellectual property as ‘a sword and a shield. 33<br />

In this model, a company actively asserts (enforces) IP<br />

rights aga<strong>in</strong>st third parties. In many cases, the process<br />

beg<strong>in</strong>s with a ‘cease and desist’ letter sent to the<br />

party allegedly <strong>in</strong>fr<strong>in</strong>g<strong>in</strong>g the IP rights and ends with a<br />

licens<strong>in</strong>g agreement (settlement) to allow the <strong>in</strong>fr<strong>in</strong>g<strong>in</strong>g<br />

party to cont<strong>in</strong>ue the use of IP rights under specific<br />

conditions and for remuneration (licence fee, royalty). In<br />

this way, a company creates a revenue stream.<br />

However, the reaction of the third party may be<br />

less amicable and it may cont<strong>in</strong>ue us<strong>in</strong>g the IP<br />

rights without authorisation. The party may run its<br />

own due diligence to assess the credibility of the<br />

<strong>in</strong>fr<strong>in</strong>gement claims, as well as ignor<strong>in</strong>g the letter and<br />

any other communication. This forces the company<br />

to consider legal steps, <strong>in</strong>clud<strong>in</strong>g a lawsuit. The less<br />

amicable approach of the third party may shift to a<br />

confrontational one, which will lead to a counterclaim<br />

and an attempt to <strong>in</strong>validate the IP rights of the<br />

company. As Palfrey expla<strong>in</strong>s, this would be the<br />

shield<strong>in</strong>g role of the IP. 34 Despite the obvious tension<br />

<strong>in</strong> such a scenario, it may end with a settlement<br />

agreement that would <strong>in</strong>clude a cross-licence.<br />

Palfrey <strong>in</strong>dicates one strong limitation of this approach:<br />

it does not work aga<strong>in</strong>st big technology breakthroughs<br />

and radically better solutions. He also states,<br />

‘That particular battle has to be won <strong>in</strong> the research and<br />

development labs, not <strong>in</strong> the courtroom.’ 35<br />

The lawsuit path is anyth<strong>in</strong>g but easy (and cheap). In<br />

addition, diverse studies have revealed the risks relat<strong>in</strong>g<br />

to patent disputes and demonstrated that patent<br />

owners (pla<strong>in</strong>tiffs) walk on th<strong>in</strong> ice:<br />

• Janicke and Ren <strong>in</strong> their research from 2005 found<br />

that about 25% of the analysed 262 dispositive<br />

cases 36 <strong>in</strong> 2002-2004 were won by the patent<br />

owner and the other 75% by the accused <strong>in</strong>fr<strong>in</strong>ger. 37<br />

• An analysis of 6,992 post-grant reviews at PTAB<br />

(USPTO) 38 of patents filed between 16 September<br />

2012 and 8 June 2017 revealed rather shock<strong>in</strong>g<br />

numbers: only 4% of petitions ended with all claims<br />

found patentable. A narrower analysis of 1,556<br />

petitions that had reached f<strong>in</strong>al written decisions,<br />

demonstrated that 69% of petitions had all claims<br />

<strong>in</strong>validated. 39<br />

• A quarterly report of the PTAB from September 2020<br />

revealed that out of 3,105 patents that had been<br />

subject to a PTAB F<strong>in</strong>al Written Decision, 2,612 of them<br />

had been determ<strong>in</strong>ed to be ‘Unpatentable/Cancelled’. 40<br />

• Another <strong>in</strong>terest<strong>in</strong>g perspective was provided <strong>in</strong> a<br />

study by Henkel and Zischka, who concluded that<br />

around 80% of all active German patents are latently<br />

<strong>in</strong>valid, either fully or partially. 41<br />

This data presents a real concern that should be<br />

<strong>in</strong>cluded <strong>in</strong> the risk-benefit assessment before<br />

launch<strong>in</strong>g any patent enforcement campaign: a patent<br />

owner may not only lose the <strong>in</strong>fr<strong>in</strong>gement dispute but<br />

also patents <strong>in</strong>volved <strong>in</strong> litigation.<br />

Take-home message: Assert<strong>in</strong>g your IP portfolio may<br />

be the only option to stop competitors from us<strong>in</strong>g<br />

or copy<strong>in</strong>g your solution and make them pay for<br />

the <strong>in</strong>fr<strong>in</strong>g<strong>in</strong>g use. However, the decision must be<br />

thoroughly analysed <strong>in</strong> consultation with your patent/<br />

IP attorney before any actions are taken.<br />

33<br />

Palfrey (n 5) 101.<br />

34<br />

Ibid 102.<br />

35<br />

Ibid 104.<br />

36<br />

‘A case <strong>in</strong> which, as it leaves the Federal Circuit, at least one claim of one patent is f<strong>in</strong>ally adjudicated to have been <strong>in</strong>fr<strong>in</strong>ged and not <strong>in</strong>valid or unenforceable<br />

(i.e., a w<strong>in</strong> for the patent owner), or <strong>in</strong> which it has been f<strong>in</strong>ally determ<strong>in</strong>ed that no claim has these characteristics (a w<strong>in</strong> for the accused <strong>in</strong>fr<strong>in</strong>ger).’ Paul M. Janicke<br />

and LiLan Ren, ‘Who W<strong>in</strong>s Patent Infr<strong>in</strong>gement Cases?’ (34 AIPLA Quarterly Journal 1, 1, 2006) 4 <br />

accessed 2 December 2022.<br />

37<br />

Ibid 5.<br />

38<br />

Patent Trial and Appeal Board of the US Patent and Trademark Office.<br />

39<br />

Josh Malone, ‘Assess<strong>in</strong>g PTAB Invalidity Rates’ (IP Watchgod, updated 24 June 2021)<br />

accessed 2 December 2022.<br />

40<br />

Ibid.<br />

41<br />

Joachim Henkel and Hans Zischka, ‘Why most patents are <strong>in</strong>valid – Extent, reasons, and potential remedies of patent <strong>in</strong>validity’ (Draft, 24 March 2015), 3<br />

accessed 2 December 2022.<br />

29

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!